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Abstract
Background: Over the past decade malaria intervention coverage has been scaled up across Africa. However, it remains
unclear what overall reduction in transmission is achievable using currently available tools.
Methods and Findings: We developed an individual-based simulation model for Plasmodium falciparum transmission in an
African context incorporating the three major vector species (Anopheles gambiae s.s., An. arabiensis, and An. funestus) with
parameters obtained by fitting to parasite prevalence data from 34 transmission settings across Africa. We incorporated the
effect of the switch to artemisinin-combination therapy (ACT) and increasing coverage of long-lasting insecticide treated
nets (LLINs) from the year 2000 onwards. We then explored the impact on transmission of continued roll-out of LLINs,
additional rounds of indoor residual spraying (IRS), mass screening and treatment (MSAT), and a future RTS,S/AS01 vaccine
in six representative settings with varying transmission intensity (as summarized by the annual entomological inoculation
rate, EIR: 1 setting with low, 3 with moderate, and 2 with high EIRs), vector–species combinations, and patterns of
seasonality. In all settings we considered a realistic target of 80% coverage of interventions. In the low-transmission setting
(EIR,3 ibppy [infectious bites per person per year]), LLINs have the potential to reduce malaria transmission to low levels
(,1% parasite prevalence in all age-groups) provided usage levels are high and sustained. In two of the moderate-
transmission settings (EIR,43 and 81 ibppy), additional rounds of IRS with DDT coupled with MSAT could drive parasite
prevalence below a 1% threshold. However, in the third (EIR = 46) with An. arabiensis prevailing, these interventions are
insufficient to reach this threshold. In both high-transmission settings (EIR,586 and 675 ibppy), either unrealistically high
coverage levels (.90%) or novel tools and/or substantial social improvements will be required, although considerable
reductions in prevalence can be achieved with existing tools and realistic coverage levels.
Conclusions: Interventions using current tools can result in major reductions in P. falciparum malaria transmission and the
associated disease burden in Africa. Reduction to the 1% parasite prevalence threshold is possible in low- to moderate-
transmission settings when vectors are primarily endophilic (indoor-resting), provided a comprehensive and sustained
intervention program is achieved through roll-out of interventions. In high-transmission settings and those in which vectors
are mainly exophilic (outdoor-resting), additional new tools that target exophagic (outdoor-biting), exophilic, and partly
zoophagic mosquitoes will be required.
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Introduction
Over the past five years, dramatic declines in malaria disease
caused by Plasmodium falciparum have been reported across a range
of settings within sub-Saharan Africa. These declines are
associated with increased distribution of long-lasting insecticide-
treated nets (LLINs) and with the switch from a failing drug
regimen to artemisinin-based combination therapies (ACT) as
first-line therapy [1–4]. Whilst this pattern of reducing disease is
encouraging, there remain many countries within Africa that
continue to have a high burden of disease and hence malaria
remains a leading cause of mortality in children under five years of
age [5]. Thus control of the disease, and ultimately elimination of
the parasite in this continent, remain major public health goals.
Eradication of malaria was attempted in the 1950s under the
auspices of the World Health Organization-led Global Malaria
Eradication Program (GMEP) [6]. Notably, Africa was not
formally included in this program despite clear evidence of the
large disease burden within the continent at that time. However,
elimination campaigns were subsequently undertaken on a smaller
scale within Africa, most prominently in two areas of moderate to
high transmission in Nigeria (the Garki project [7,8]) and on the
Kenyan/Tanzanian border (the Pare-Taveta project [9]), but also
periodically in areas of lower transmission including the Kenyan
highlands [10] and the island of Madagascar [11]. These
campaigns included frequent insecticide spraying of houses to
reduce the vector populations and rounds of mass treatment to
reduce the human infectious reservoir. Whilst substantial declines
in infection and disease were observed in all of these campaigns,
the control measures were not sufficient to eliminate the parasite
on a short time scale, and failure to sustain control programs
inevitably led to rebound of infection and disease in later years.
This under-performance was perceived as a lack of success by past
eradication attempts, which may in part be attributed to over-
optimism about what could have been achieved with the tools then
available [12].
Two years ago, following a renewed commitment to malaria
control from donor organizations, the focus shifted again to
malaria eradication as an ultimate goal. Previously, many
countries had already intensified their own malaria control
programs with much success in reducing both the burden of
disease and ongoing transmission [1–4,13,14]. However, Africa
poses the biggest challenge to a global eradication initiative, given
the heterogeneous yet ubiquitous nature of P. falciparum transmis-
sion across much of the continent. Levels of transmission in Africa
range from absent or low in many urban areas, through epidemic
outbreaks in the highlands, to highly seasonal or perennial
transmission in rural areas [15,16]. This variable transmission
pattern is further complicated by local variation in the major
Anopheles vector populations that sustain transmission (principally
An. gambiae s.l. and An. funestus, although approximately 70 relevant
species have been identified worldwide [17]). Of the 47 countries
within sub-Saharan Africa, the majority are currently classified by
WHO/Roll-Back Malaria as being in the control stage and thus
need to scale up interventions to sustain control and reduce the
burden of disease via a reduction in transmission [18]. On the
northern borders of the continent, transmission is already low,
with Egypt and Algeria in the elimination phase and Morocco and
Mauritius having interrupted local transmission. Similarly, in the
southernmost countries, a sustained move towards local control
and potentially elimination in border areas has been agreed upon
via cooperation with neighbouring countries (the ‘‘elimination
eight’’) [19]. On the island of Zanzibar, a highly successful control
program has reduced transmission to very low levels. However, a
recent assessment of the feasibility of moving to elimination
concluded that, whilst it is technically feasible to reduce local
transmission to zero in this setting, the resources, both financial
and operational, required to sustain elimination in the face of
repeated reintroduction from mainland Africa make this a difficult
prospect [20].
Compared to the past campaigns in the 1950s, additional tools
are now available which, combined with sustained policy
commitment, may make local elimination achievable in some
settings and can aid control of disease by dramatically reducing
malaria prevalence in countries with high rates of ongoing
transmission. These include new LLINs, which have increased
killing effects on the vectors compared to traditional nets and are
more durable [21–25], and ACTs, which, through their
gametocytocidal effect, can impact transmission from humans to
vectors [26,27]. In addition, a pre-erythrocytic malaria vaccine,
RTS,S, has shown promising results in Phase II trials [28–34] and
could soon contribute to elimination programs. National control
agencies have varying levels of resources but can rarely implement
all major control interventions at a given time. Understanding how
to choose policy that is appropriate to the local setting is therefore
key to effective control. Whilst the efficacies of most interventions
have been individually evaluated in the field, the impact of
different combinations of these is not clear. Field trials will be
important to inform control policies but will be able to test only a
few of the combinations of interventions in a limited number of
settings.
Mathematical models provide a tool with which to explore the
expected impact of different interventions against malaria, both
individually and in combination, on a range of program endpoints
[26,35–40]. Whilst simple models can provide important general
insights, the heterogeneity in transmission intensity [41–43], the
variability in vector species composition and associated bionomics
[17,35], and the seasonality in vector populations [44] are all
important factors that affect the transmission potential of a site and
the likely impact of intervention packages. We therefore
constructed an individual-based simulation model which captures
these key factors while remaining sufficiently mathematically
tractable to enable the baseline model parameters to be rigorously
fitted to data within a Bayesian framework. The model includes
the suite of current tools most often employed by (or likely to be
employed by) National Malaria Control Programs—namely,
LLINs, IRS, ACTs in case treatment and in mass treatment
campaigns, and a vaccine with characteristics similar to the
RTS,S/AS01 vaccine now in Phase III trials. The principal aim of
the modelling presented here is to explore the potential for current
control measures to reduce parasite prevalence to a low level
(defined here as below a threshold of 1% prevalence across all age
groups detected through microscopy which represents a level
below which surveillance would likely switch to case detection) as
laid out in the control phase of the global elimination framework
[45]. We illustrate our results by applying our model to six well-
characterized transmission sites which represent the full range of
transmission intensity–vector species combinations and seasonality
patterns most commonly observed across Africa.
Methods
Simulation Model for Malaria Transmission Dynamics
We developed a stochastic simulation model for P. falciparum
transmission dynamics in which people are represented as
individuals while vectors are represented as aggregated popula-
tions, stratified by species. The model builds on an earlier
compartmental model which incorporates the acquisition and loss
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of immunity to disease and to detectable parasitaemia [46,47], but
is extended to incorporate infection-blocking immunity and
heterogeneity in biting rates. Full technical details are given in
Protocol S1 and the flow diagram is presented in Figure 1A.
Briefly, individuals begin life susceptible (S) to infection but with
partial maternal immunity determined by the level of immunity in
women of childbearing age. Maternal immunity decays in the first
six months of life, thereby increasing susceptibility to disease.
Individuals become infected at a rate determined by the force of
infection in the population (L), which is determined by the ratio of
vectors to humans, the biting rate per mosquito on humans, the
proportion of infectious mosquitoes in the vector population, and
the person’s level of anti-infection immunity. On infection, they
pass through the liver (pre-patent) stage and then either develop
clinical disease (with a probability w determined by their current
level of anti-disease immunity) or develop patent (detectable under
microscopy) asymptomatic infection (12w). Those who develop
clinical disease have a fixed probability (fT) of being treated
successfully (T), in which case they will clear infection and,
depending on the drug, enter (with rate rT) a period of
prophylactic protection (P) before returning (rP) to being
susceptible to new infection. Those who fail treatment (12fT) are
assumed to eventually clear disease (D) and become patently
asymptomatic (A) with rate rD. From patent asymptomatic
infection, individuals will eventually move to a sub-patent stage
(U) which can be an important component of the infectious
reservoir [48], at a rate (rA) that depends on their current level of
anti-parasite immunity. Sub-patent infection is eventually cleared
(rU) and individuals return to being fully susceptible. From all
infected states, acquiring a new infection in the presence of an
existing infection (superinfection) is possible. Rather than explicitly
tracking mixed infections, we assume that the new infection
dominates and thus individuals move to either the clinical disease
or asymptomatic states dependent on their level of anti-disease
immunity. Individuals become infectious to vectors, at differing
rates, in the clinical disease, patent and sub-patent asymptomatic
Figure 1. Transmission model; EIR, prevalence and seasonality; and infectious reservoir. (A) Flow diagram for the human component of
the model. S, susceptible; T, treated clinical disease; D, untreated clinical disease; P, prophylaxis; A, asymptomatic patent infection; U, asymptomatic
sub-patent infection. (B) The relationship between EIR and parasite prevalence in children under 15 y. Solid line: fitted relationship; filled circles: data
representative of this age group; open circles: data from other age groups (mostly younger) used in the model fitting. (C) The relationship between
transmission intensity characterized by EIR and seasonality, defined as the proportion of EIR over a single calendar year that occurs within the peak
three months of transmission. The colours of the markers indicate the different transmission settings and the shapes the species. (D) The estimated
age-specific infectious reservoir for the different transmission settings defined in (C), with the same colours as (C). This is defined as the product of the
age-specific biting rate, age-specific prevalence states (T, D, A, and U), state-specific onward infectivity to mosquitoes and the size of the population
at this age.
doi:10.1371/journal.pmed.1000324.g001
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stages—the states that compose the human infectious reservoir
(Figure 1D). Four types of human immunity are included and
are modelled dynamically. Maternal immunity, which protects
against clinical disease, is assumed to decay exponentially from
birth. Anti-disease immunity, which reduces the probability of
developing clinical symptoms on infection, and infection-blocking
immunity, are both exposure-driven whilst anti-parasite immunity,
in which individuals control parasite densities and thus leave the
patent infection state more quickly, is assumed to develop with
age, conditional on having been exposed.
Three Anopheles vector species (An. gambiae s.s., An. funestus, and
An. arabiensis) are modelled explicitly as the predominant vectors in
the transmission sites that we consider. Vectors begin susceptible
and on taking an infectious bite move into a latent state. From this
they become infectious to humans, with infectivity determined by
their human blood index (HBI) and biting rate and are assumed
never to recover before death. Vector density is assumed to follow
a seasonal pattern as determined by fitting an appropriate
functional form to entomological data from the areas considered
(see Table 1 and Protocol S4).
Model Parameterization
Model parameterization was undertaken in several stages. First,
a literature search was undertaken to formulate prior distributions
for all model parameters. Where there was no information in the
literature, vague priors were used or parameters were fixed if they
could not be identified from subsequent model fitting. The human
model parameters were estimated by fitting the equilibrium model
conditional on EIR using Bayesian Markov Chain Monte Carlo
(MCMC) methods to data on the stationary distributions of
parasite prevalence (by both microscopy and PCR) by age from 34
locations across a wide range of transmission intensities from
Africa (see Protocol S3) and of clinical disease incidence from two
settings in Senegal [49]. Site-specific prior distributions for EIR
were used based on published data ([50] and Protocol S3). By
fitting the model to these data we were able to characterize the
relationship between EIR (ibppy, the number of infectious bites
per person per year) and parasite prevalence (Figure 1B). The
parameters determining the onward transmissibility of the human
infectious stages (clinical disease, patent and sub-patent infection)
to mosquitoes were obtained by model fitting to data from human
feeding studies and the Garki project [7,51–54]. These parameters
combined with parasite prevalence determine the age profile of the
infectious reservoir (Figure 1D) [55,56]. Only age-targeted
strategies are sensitive to this profile. Parameters for the vector
model were taken from the literature. A full listing of model
parameters, their prior and posterior medians, and literature
sources are given in Table S3.1 in Protocol S3. To run the model
in specific settings, data on vector species composition, their
seasonal profile, and the intensity of transmission (EIR) were
extracted from the literature (Table 1, Figure 1C, Figure 2, and
Protocol S4). A functional form was fitted to monthly data on
either EIR or vector density to enable a single seasonal driver
input (emergence of vectors) into the model. Full details of the
settings and the seasonal profile fitting are in Protocol S4.
Interventions
The implementation of each intervention is described briefly
below. Full mathematical details and tables of parameter values
are provided in Protocols S2 and S3.
Long-lasting insecticide-treated nets. We adapted an
existing model [36] to our individual-based framework. Nets are
assumed to have four effects: direct killing of a mosquito that lands
on them, repellency which results in a longer gonotrophic cycle
and possible diversion to a non-human blood host, a direct
protective effect for the individual sleeping under the net, and a
reduction in transmission from infected individuals sleeping under
the net to susceptible mosquitoes. The degree of indoor-biting
(endophagic) behaviour for the different species is incorporated
into the model when assessing the LLIN effect. These behaviours
are assumed to remain constant throughout the intervention.
Indoor residual spraying. IRS was added to the LLIN
model as an additional intervention which can kill mosquitoes as
they rest within the house or repel them before they feed. In the
model the repellency effect extends the duration of the
gonotrophic cycle in the same way as the repellency effect of
LLINs. For IRS the killing effect depends primarily on the indoor-
resting (endophilic) nature of the species as well as its HBI.
Simulations assumed a DDT-like insecticide with a half-life of
6 mo which acts by repelling and killing mosquitoes [57].
Switch to ACT as first-line treatment. Effective treatment
(i.e., treatment which fully clears infection) was assumed to be
given to a proportion of those developing clinical disease.
Treatment failures were not explicitly modelled but are assumed
Table 1. Summary of the six malaria transmission settings considered here.
Country Location Population
Type of
Transmission
Reported
Annual EIR
(ibppy)
Fitted
Annual EIR
(ibppy)
Anopheles Species Relative
Abundance Reference
Cameroon Nkoteng Rural Moderate, perennial 94 81 72% An. funestus; 28% An.
gambiae s.s.
[97]
Democratic Republic
of Congo
Kinkole Rural Moderate, perennial 48 43 Nearly 100% An. gambiae s.s. [98]
Ghana Kassena-Nankana
District
Rural High, seasonal 630 586 60% An. gambiae s.s.; 40% An.
funestus
[99]
Mozambique Matola, Maputo Coastal
suburb of
capital
Moderate, perennial 28 46 42% An. arabiensis; 46% An. funestus
(additional 12% An. coustani are not
considered here)
[100]
Tanzania Matimbwa Rural High, seasonal 703 675 85% An. gambiae s.s.; 10% An.
funestus; 5% An. arabiensis
[101]
Uganda Kjenjojo Kasiina Rural Low 7 3 65% An. gambiae s.s.; 35% An.
funestus
[102]
doi:10.1371/journal.pmed.1000324.t001
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to follow the same infection path as untreated infections. The half-
life of the drugs pre-ACT (where we assume sulphadoxine-
pyrimethamine [SP] was first-line therapy) and following ACT
introduction determine the period of prophylaxis. In addition, the
gametocytocidal effect of ACTs was incorporated as a reduction in
onward infectiousness as in a previous model, based on data from
human-to-mosquito transmission experiments involving treated
patients [27].
Mass drug administration. We considered the impact of a
mass screening and treatment approach (MSAT) using a single
dose of an ACT. We assumed that a rapid diagnostic test (RDT)
would have approximately the same sensitivity as microscopy and
thus all those in the clinical disease or asymptomatic patent
infection stages would receive the drug, but that the uninfected
and sub-patent infected individuals would not. The ACT was
assumed to clear any infection present and provide a period of
prophylactic protection (25 d, corresponding to an artemisinin
coupled with a drug such as SP). The coverage level refers to the
number of individuals screened.
Pre-erythrocytic vaccine. A pre-erythroyctic vaccine was
assumed to reduce the probability of transmission from mosquitoes
to people. It remains unclear whether this lower exposure to
infection will affect the development of anti-disease immunity.
Here we assume that it does but that it has no effect on the
development of anti-infection immunity. Individual vaccine
efficacy was assumed to decay exponentially with a half-life of
3 y. The vaccine is delivered through the Expanded Program for
Immunization (EPI) and given at ages 3–5 mo, or as a mass
vaccination program across all ages every 3 y.
Transmission Settings
We considered the impact of these interventions, individually
and in combination, in six different settings that characterize the
spectrum of transmission patterns of P. falciparum across Africa.
These settings range in transmission intensity from measured EIRs
of approximately 5 to over 500, translating in our model to
parasite prevalence in 2- to 10-year-olds of 14% to 85%. In 2007,
80% of Africa’s population was estimated to reside in an area with
parasite prevalence in 2- to 10-year-olds of .5% and 50% in an
area with prevalence .40% [16]. These specific settings,
summarized in Table 1, Figure 1C, and Figure 2, were chosen
because of the large number of both entomological and clinical
Figure 2. Fitted seasonal profile of EIR for the six transmission settings by vector species. The fitted seasonal profiles of EIR per day and
fitted annual EIR were obtained by fitting a transformed sinusoidal function to reported time series of either EIR or mosquito densities in the settings
(see Protocol S4). Grey, total; red, An. gambiae s.s.; blue, An. funestus; green, An. arabiensis. (A) Nkoteng, Cameroon; (B) Kinkole, DRC; (C) Kassena-
Nankana District, Ghana; (D) Matola, Maputo, Mozambique; (E) Matimbwa, Tanzania; (F) Kjenjojo Kasiina, Uganda.
doi:10.1371/journal.pmed.1000324.g002
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studies undertaken in these areas and to represent patterns of
perennial/seasonal transmission of varying intensity and with
different mixes of Anopheles species. We fitted the model to data
from these settings, which we take as our baseline scenarios.
For each scenario, we present the mean of ten simulation runs in a
population of 10,000 individuals, which was sufficient to approximate
the dynamics in a larger population. The population size was
assumed to be static over time, with age structure based on data from
Tanzania. After introducing infection, the model was run for 50 y to
reach equilibrium representing the situation in the year 2000.
Between 2000 and 2010 we increased the distribution of LLINs from
a baseline of zero coverage to a maximum of 20% coverage [58] and
implemented a switch to ACT as first-line therapy in the year 2000.
Combinations of interventions were then introduced from 2010
onwards. Note that this does not necessarily reflect the true
intervention programs in place in these settings in these years, and
hence model outputs do not directly predict expected patterns in
these settings; rather they give an indication of the likely effectiveness
of the modelled intervention packages in different setting types.
Intervention Package Scenarios
Coverage here is defined as the proportion of individuals
receiving an intervention (for LLINs ownership, for vaccination
those receiving the vaccine, for IRS those that reside in houses
where spraying occurs, and for MSAT the number of individuals
screened). We separately consider the impact of adherence/usage
for LLINs, which is assumed to decay over time. This proportion
of people using LLINs is termed effective coverage. For IRS we
assume no loss of adherence. For MSAT we assume that all those
who are screened and positive on microscopy take the drug.
Similarly, for the vaccine we assume that those offered it accept.
Finally, for all interventions there is a decay in protective efficacy
over time for those who have received and use the intervention.
For LLINs this is due to wear-and-tear and loss of insecticidal
effect. For IRS we model the loss of insecticidal effect. For vaccines
we assume that efficacy declines through waning protection.
Unless stated otherwise we assumed that IRS and MSAT were
given at 80% coverage (the maximum achievable in well-managed
control programs [59]) and the vaccine at 90% coverage (based on
EPI distribution statistics). For the roll-out of LLINs we considered
two realistic scenarios. In the first, distribution was increased
gradually to a maximum of 80% within 5 y and a new net was
distributed to individuals every 5 y. In the second, we assumed
almost immediate distribution at 80% coverage, redistribution
every 5 y, plus delivery of a net to 80% of newborn infants and an
average of 0.75 adults for every infant who receives a net
(Figure 3A). These coverage levels are similar to the targets set for
2010 for scaling up for impact in the Global Malaria Action Plan
[18]. In both scenarios, we assume that LLIN use wanes over time
so that effective coverage is lower. Here we assumed an
exponential decay at a rate 0.2 per year so that after 5 y effective
coverage is approximately 37% of the baseline level. We also
considered the impact of a theoretical (unachievable) maximum of
100% coverage with LLINs coupled with no decay in usage over
time (Figure 3A). Protective efficacy of the nets due to decaying
insecticide efficacy and wear-and-tear was assumed to decay
exponentially with a half-life of 2.64 y (Protocol S3 and [60]). We
did not consider any decay in effective coverage of IRS as we
assumed that coverage remained constant at each round (i.e.,
people do not refuse to have their house sprayed as the
intervention goes on). The protective efficacy of DDT was
assumed to decay exponentially with a half-life of 6 mo (Protocol
S3 and [57]). Adherence to LLINs given receipt was assumed to be
independent of IRS acceptance.
We undertook preliminary runs for IRS and MSAT to identify the
optimal time of year for annual programs. The optimal time was
defined on the basis of providing the maximum reduction in mean
prevalence of parasitaemia across all age groups in year 10 of the
intervention campaign. We found that in those settings which have a
clear seasonal peak in the EIR, it is always optimal to spray just before
the upward trend in EIR. In settings with less seasonality, there is less
difference in impact, but spraying at the start of the main transmission
season tends to remain optimal. In contrast, across most settings, the
optimal time of year to mass treat in terms of reducing overall
prevalence of asexual parasitaemia as an endpoint is at the beginning
of the period of lowest EIR (also shown in [61]), which generally
occurs approximately 2 mo after peak slide prevalence. For scenarios
in which IRS and MSAT were undertaken every 6 mo, they were
implemented at the optimal time of year as defined above, plus 6 mo
thereafter.
Effective coverage and protective efficacy do not alone
determine intervention effectiveness, as they also depend on
whether the same individuals receive multiple interventions or
whether interventions are randomly distributed across the
population. We therefore allowed correlations between repeat
distribution for each individual intervention (where a correlation
of 0 means that redistribution is completely random and of 1 that
redistribution always occurs to those who had previously received
the intervention). We also allowed correlations between receiving
LLINs, IRS, and MSAT. Here a positive correlation means that
individuals who receive one intervention are also more likely to
receive the other (which could reflect access to interventions) whilst
a negative correlation means that those who receive one
intervention tend not to receive the other (which would reflect a
propensity not to use multiple interventions).
As our focus is to consider intervention packages aimed at
reducing transmission, our primary outcome was the annual mean
prevalence of asexual parasitaemia as measured by microscopy in
the whole population up to 25 y following the start of the
intervention program. We chose this rather than prevalence
restricted to children as it enables us to correctly compare age-
targeted interventions. We specifically do not focus on short-term
‘‘predictions’’ or timelines, as our sensitivity analysis shows that
these are highly dependent on parameters relating to the loss of
acquired immunity (which impact the fitted duration of infection).
Currently these parameters are not well-estimated from the
available data (see Section 5.2.1 in Protocol S5, and Box 1).
Furthermore, time scales of impact will inevitably depend on the
speed with which scale-up of interventions occurs and so cannot be
reliably predicted without detailed assessment of local situations.
Software
A user-friendly software package for reproducing the simula-
tions presented here, as well as other potential combinations of the
interventions included in this paper, is freely available to download
from our Web site (http://www1.imperial.ac.uk/medicine/about/
divisions/publichealth/ide/research_groups/malaria/). A short
summary of the interface is provided in Protocol S6.
Results
Continued Scale-Up of LLINs
Continued scale-up of LLINs from the baseline assumption of
20% coverage could potentially reduce transmission across all six
transmission settings, given that the dominant vector species in
these settings are primarily endophagic and their peak biting times
coincide closely with normal sleeping hours [62] (provided changes
in mosquito behaviour in response to the interventions are not
Strategies to Reduce Malaria
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Figure 3. Impact on parasite prevalence of LLINs alone. (A) Example of the ways in which coverage of LLINs is considered to increase in
various model scenarios. Baseline (blue): our baseline scenario in which 80% coverage is achieved over five years but adherence also decays between
net distribution rounds; rapid (brown): as baseline but with more rapid scale-up to 80% coverage; rapid, no drop-out (green): rapid scale-up to 80%
coverage with no decay in adherence; 100% (yellow): 100% coverage with no decay in adherence (theoretical maximum effect). (B) Model-predicted
impact on parasite prevalence over calendar time of four scenarios for LLIN scale-up combined with an earlier switch to ACT as first-line therapy in
Kjenjojo Kasiina, Uganda. (C) Final parasite prevalence and (D) absolute reduction in parasite prevalence after 15 years of a sustained intervention
program in the six transmission settings with the baseline scenario for LLIN distribution, the rapid scenario for LLIN distribution, and the rapid
scenario with no loss of adherence for LLIN distribution.
doi:10.1371/journal.pmed.1000324.g003
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dramatic). However, the magnitude of the effect will depend not
only on the intensity of transmission in each setting but also how
roll-out is achieved, the final level of coverage, adherence to LLIN
use, and the decay in insecticide effectiveness over time. Figure 3A
shows four potential scenarios for scale-up if nets are redistributed
every 5 y. Theoretically, the greatest impact is achieved with rapid
deployment, 100% coverage, and perfect adherence. However,
even at this unrealistically high level, the efficacy will be less than
its maximum due to decaying effectiveness of the insecticide. Even
at the target coverage levels of 80%, with gradual roll-out and
realistic adherence, effective coverage levels can, on average, be as
low as 50% (Figure 3A). The additional decay in insecticide
efficacy over time can result in protective coverage levels as low as
30%. This is even without the additional limitation of an
interrupted supply chain, which is likely to reduce effective
coverage further [63].
In the low-transmission setting of Kjenjojo Kasiina, Uganda,
the basic reproduction number (R0) is already close to 1 in the
absence of additional interventions. Thus, parasite prevalence can
be reduced to below the 1% threshold over a 15 y time horizon
with LLIN use alone (Figure 3B). However, even in this relatively
low-transmission setting, high levels of coverage and adherence are
required. Furthermore, with decaying adherence in their use it is
likely that transmission will be sustained, albeit at a low level.
Furthermore, if LLINs have a lower killing effect than that
assumed here, our model would predict sustained transmission in
this setting (Figure S5.6 in Protocol S5).
In contrast, in the moderate-transmission settings of Nkoteng
(Cameroon), Kinkole (Democratic Republic of Congo or DRC),
and Maputo (Mozambique), and in the high-transmission settings
of Kassena Nankana District (KND) (Ghana), and Matimbwa
(Tanzania), scale-up of LLINs alone does not reduce parasite
prevalence to below 1%, even over longer time periods (Figure 3C).
We can, however, expect to see dramatic declines in the first five
years of the program followed by an increase to new endemic
levels as levels of immunity in the population change (Figure S5.1
in Protocol S5). The time scale of this rebound is difficult to
ascertain from current data due to uncertainty in the rate of loss of
acquired immunity (see section 5.2.1 in Protocol S5, and Box 1).
In high-transmission settings, with continued scale-up of LLINs
to 80% coverage within five years, the absolute drop in prevalence
is between 5% and 10%. If rapid scale-up occurs and adherence is
sustained, drops in prevalence of 20%–25% can be expected
(Figure 3D). However, despite the smallest relative impact
occurring in the high-transmission settings, because most cases
of infection and disease occur in these settings, the absolute impact
in terms of numbers of infections averted will be greater. Thus, in
terms of reduction in infections per net distributed, impact will be
greatest in these high-transmission settings.
Additional Use of IRS and MSAT
Whilst continued scale-up of LLINs is predicted to reduce
transmission substantially, under realistic assumptions about the
level of coverage and adherence to LLIN use, additional tools will
be necessary in many settings. In Kjenjojo Kasiina, Uganda,
yearly rounds of IRS with DDT combined with continued scale-
up of LLINs to 80% coverage is predicted to locally eliminate
transmission (Figure 4A). Yearly rounds of MSAT as an alternative
to IRS tend to have less impact although this would also achieve a
reduction below the 1% parasite prevalence threshold.
In the moderate-transmission setting of Kinkole, DRC, more
intensive rounds are required. Thus, in this setting, twice yearly
IRS and MSAT are required to reduce parasite prevalence below
the 1% threshold (Figure 4B). In contrast, in the slightly higher-
transmission setting of Nkoteng, Cameroon, this is not sufficient in
itself and additional faster scale-up of LLINs is needed to achieve
this threshold (Figure 4D). In Maputo, Mozambique, in which
transmission intensity as measured by EIR is similar to Kinkole,
DRC and lower than Nkoteng, Cameroon, even these more
intense programs are unable to reduce prevalence below the 1%
threshold (Figure 4C). This is due to the high proportion of
transmission that occurs via An. arabiensis in this setting, whose
more exophilic behaviour reduces the impact of IRS on
transmission. Assuming a lower degree of exophilic behaviour of
this species compared to our baseline assumption, this conclusion
continues to hold (section 5.2.2 in Protocol S5). In all three
moderate-transmission settings, IRS with an insecticide similar to
lambdacyhalothrin (which is less repellent and hence more lethal
but has a shorter half-life than DDT) is predicted to have a lesser
effect on transmission than DDT (Figure S5.7 in Protocol S5).
In both high-transmission settings (KND, Ghana and Ma-
timbwa, Tanzania), current tools are insufficient to reduce parasite
prevalence below the 1% threshold (Figure 4E and 4F; see also
higher levels of adherence and coverage in Figure S5.3 in Protocol
S5, and higher frequency of MSAT in Figure S5.8 in Protocol S5).
However, in both settings, an intense program involving rapid
scale-up of LLINs with sustained adherence and twice-yearly
rounds of MSAT and IRS could result in marked declines in
prevalence from 60% to 10% in the population as a whole
(Figure 4E and 4F). However, in these settings, the interventions
would need to be sustained indefinitely to maintain this new
endemic level. Yearly IRS and MSAT combined with 80%
coverage of LLINs is predicted to reduce parasite prevalence after
15 y to below 10% in moderate transmission settings and below
25% in high-transmission settings (Figure 4G). Again, the absolute
reduction will be greatest in the latter, with a 40%–50% drop in
parasite prevalence in these settings (Figure 4H).
Targeting and Overlap in Intervention Coverage
LLIN distribution programs initially focused on young children
as one of the high-risk groups for developing severe disease.
However, as shown in Figure 5A and elsewhere [23,24], this
strategy is unlikely to have an additional impact on transmission,
because the youngest children tend not to be major contributors to
the infectious reservoir (Figure 1D). However, if limited coverage is
achievable, substantially greater reductions in prevalence could be
Box 1. Uncertain Parameters
Whilst models can be useful tools in setting realistic
expectations for intervention programs, some key param-
eters in our current model are based on limited data.
Further empirical work in these areas could improve future
models. These include:
(a) The duration of natural infection and the extent to which
super-infection prolongs this duration or increases
infectivity;
(b) The rate of acquisition of immunity at different transmis-
sion intensities, and the rate of loss of immunity when
transmission is reduced;
(c) The bionomics of the principal vector species and the
impact of vector-targeted interventions on them;
(d) Detailed data on the speed with which coverage of
interventions is scaled up, heterogeneity in coverage
levels achieved, and the degree of adherence to the
interventions over time.
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Figure 4. Impact of combining LLINs with IRS and MSAT. (A–F) Impact of intervention scenarios incorporating IRS and MSAT on parasite
prevalence in the six transmission settings. All scenarios include the earlier switch to ACT as first-line therapy. ‘‘LLIN only’’ uses the baseline scale-up
for coverage. All other scenarios include LLIN scale-up using the baseline scenario except where noted. (G and H) Final parasite prevalence and
absolute reduction in prevalence after 15 years of a sustained intervention program in the six transmission settings with baseline scenario for LLIN
distribution; baseline LLIN + yearly MSAT; baseline LLIN + yearly IRS; baseline LLIN + yearly MSAT + yearly IRS.
doi:10.1371/journal.pmed.1000324.g004
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Figure 5. The effect of non-random distribution of interventions. (A and B) Parasite prevalence after 15 years of an intervention program as a
function of the target coverage of (A) LLIN distribution and (B) MSAT for Kinkole, DRC. Blue: if the intervention is distributed randomly; green: if the
intervention is preferentially distributed to the youngest children; red: if the intervention is preferentially distributed to those who are bitten most
frequently (excluding age dependency in biting rates). (C and D) Parasite prevalence after 15 years of a single intervention program as a function of
the frequency of the intervention and whether successive rounds are given randomly (green) or to the same people (purple) for Kinkole, DRC. (C) IRS;
(D) MSAT. (E and F) Parasite prevalence in all individuals (red), in 2- to 10-year-olds (blue) and EIR (green) after 15 years of a combined intervention
program as a function of the correlation in receipt of the two interventions for KND, Ghana. A correlation of 0 represents random distribution at each
round, 1 represents those receiving one intervention also receive the other and 21 represents those receiving one intervention do not receive the
other. (E) IRS and LLIN; (F) IRS and MSAT. For (E) and (F) there is 50% coverage per round for IRS and MSAT and the baseline scenario for LLINs.
doi:10.1371/journal.pmed.1000324.g005
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obtained if, for a given level of distribution, nets were targeted
towards those living in the local foci of transmission which impact
strongly on sustaining transmission [38,42,43,64]. Thus in
Kinkole, DRC, in a program of LLIN distribution with a low
20% coverage, if distribution is prioritised to those at highest risk
we could expect a reduction in prevalence after 15 y of
approximately 6% compared to a reduction of 3% if the same
number of nets were distributed randomly. A similar picture
emerges for MSAT programs (Figure 5B), although the effect of
targeting is greater for LLINs because in addition to their direct
protective effect, they kill mosquitoes in proportion to the rate at
which the protected person would have been bitten.
With any intervention, it is likely that the same individuals or
villages will tend to access the intervention at each distribution
round. Thus for example, if 80% coverage of LLINs is achieved,
but at each redistribution the same 80% receive the interven-
tion, then after three rounds of redistribution the percentage of
the population ever receiving an LLIN is 80%. However, if this
80% coverage reflects random distribution, then after three
rounds the percentage of the population ever receiving an LLIN
is 1006(120.260.260.2) = 99.2%. Figure 5C and 5D shows the
predicted effect of rounds of IRS and MSAT between these two
extreme (systematic versus random coverage) scenarios. In both
cases, assuming random distribution results in an overes-
timate of the effect of the intervention, and this difference
increases the more frequently IRS or MSAT is undertaken.
Thus, to optimize program effectiveness it is necessary to ensure
that as wide a proportion of the target population is reached by
the intervention.
In addition to correlations between those who receive an
individual intervention, there is likely to be overlap in those who
are offered different interventions. This is likely to be most strongly
correlated for IRS and LLINs, given the perception of these
interventions as providing direct protection to the individual or
household. A positive correlation will occur if the same individuals
access the interventions. Under these scenarios, we can expect the
least impact of the intervention program (Figure 5E). However, if
uptake is negatively correlated, for example if those who are
offered IRS and LLINs choose only to have one, for the same
overall coverage levels of the individual interventions total
population coverage is increased over and above naı¨ve expecta-
tions assuming both are randomly distributed. This increased total
coverage results in the largest reductions in transmission
(Figure 5E). Similar effects are observed for IRS and MSAT,
although again, this is not as pronounced as for LLINs given that
there is less redundancy between IRS and MSAT than between
two antivectorial measures (Figure 5F).
Additional Impact of RTS,S/AS01 Vaccine
In the low-transmission setting of Kjenjojo Kasiina, Uganda,
RTS,S (when it becomes available) could further reduce
transmission and thus negate the need for additional rounds of
IRS to speed declines. As found by others [65,66], vaccination at
birth under the EPI is expected to have relatively little impact
either with or without additional rounds of MSAT (Figure 6A). If
mass vaccination every 3 y is undertaken as an alternative
alongside the baseline scale-up of LLINs to 80% coverage,
prevalence is predicted to fall to under 1%.
In the moderate transmission settings of Kinkole, DRC
(Figure 6C), Maputo, Mozambique (Figure 6D), and Nkoteng,
Cameroon (Figure 6E), continuation of programs incorporating
IRS and MSAT in addition to LLIN distribution will be needed
even if a vaccine is available. However, with a mass vaccination
program prevalence in all three sites can be driven below 5%. In
Maputo especially, where IRS is predicted to be less effective, an
additional vaccination program has a noticeable further impact on
prevalence. In both high transmission settings (KND, Ghana,
Figure 6F; and Matimbwa, Tanzania, results not shown), mass
vaccination results in modest reductions in prevalence. Across all
transmission settings, a more efficacious vaccine with a longer
duration of protection would further reduce transmission (section
5.2.6 in Protocol S5).
Discussion
If deployed in combination, current interventions can result in
substantial declines in malaria prevalence across a wide range of
transmission settings. Our results show that in areas with relatively
low transmission (EIR,10 ibppy), increased distribution and use
of LLINs, coupled with the switch to an effective ACT as first-line
therapy, could reduce transmission to very low levels if high levels
of coverage and adherence are achieved. Defining low-transmis-
sion areas as those where parasite prevalence in 2- to 10-year-olds
is under 25%, approximately 20%–50% of individuals living in
areas of stable risk of P. falciparum transmission in Africa live in
such settings [16]. Additional use of IRS and/or MSAT in these
settings would speed this reduction and also allow overall parasite
prevalence to be reduced to,1% even if adherence to LLIN use is
not perfect. These results agree with recent observations made in a
very low transmission setting in Western Kenya, in which the
parasite appears to have been eliminated in an area in which ACT
and LLIN usage have been coupled with IRS rounds [67]. Large
reductions have also been achieved in Zanzibar, where the
preintervention parasite prevalence was 9% in children aged 0 to
5 y and 12.9% in children aged 6 to 14 y [13]. After a switch to
ACT as first-line therapy and high coverage of both LLINs and
IRS rounds from 2003, parasite prevalence in all age groups is
now well below the 1% threshold. The challenge in such settings is
to sustain interventions at a sufficient level to maintain effective
control in the face of reintroduction from neighbouring areas via
human migration and travel.
In some moderate-transmission settings it is also possible to
reduce parasite prevalence below the 1% threshold with existing
tools. In our example settings, this could be achieved in Kinkole,
DRC where the endemic EIR was 48 ibppy if an intensive
program of twice-yearly IRS and MSAT were combined with
increasing LLIN coverage to 80% levels. In the slightly higher
transmission setting of Nkoteng, Cameroon (EIR = 96 ibppy),
current tools could reduce transmission below the 1% threshold
but in this case (perhaps unrealistically) high levels of adherence to
LLIN use would also be needed. Thus the first phase of
elimination programs is achievable in many areas in which the
LLIN and IRS in combination are effective (that is, in areas with
primarily endophilic vectors). Additional use of MSAT, to date not
considered by many programs, has the potential to speed further
declines in prevalence.
We considered one area, Maputo, Mozambique, in which the
high proportion of An. arabiensis (exhibiting a high degree of
exophilic behaviour), made elimination more difficult. Whilst the
scale of the declines that our model predicts are similar to those
observed in an IRS-based campaign in that area (that commenced
in 2000 using Bendiocarb rather than DDT [4]), this study also
demonstrated a greater impact on the population of An. arabiensis
compared to that resulting from our model. This may be because
our estimate of the degree of exophilic behaviour is too high
(see Protocol S3) or because mosquito behaviour changes both
with season and with setting [35,68–71] and requires further
exploration.
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Figure 6. Impact of additional vaccination on parasite prevalence in the different transmission settings. All runs assume the RTS,S
vaccine is 50% efficacious and has a half-life of 3 years. PEV at EPI denotes the pre-erythrocytic vaccine being given through the Expanded Program
on Immunization, whilst mass PEV denotes a mass vaccination campaign. All runs include LLINs. (A) PEV at EPI with or without additional MSAT in
Kjenjojo, Uganda (B) Mass PEV with or without additional MSAT in Kjenjojo, Uganda (C to F) MSAT and IRS with mass PEV in: (C) Kinkole, DRC, (D)
Maputo, Mozambique, (E) Nkoteng, Cameroon and (F) KND, Ghana.
doi:10.1371/journal.pmed.1000324.g006
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In high transmission intensity settings, current tools can be used
to substantially reduce transmission and the associated disease
burden, but are insufficient to drive prevalence below the pre-
elimination threshold. This finding is not surprising given the high
basic reproduction numbers previously estimated in large parts of
sub-Saharan Africa [43]. Such outcomes have been observed in
the Bioko Island control program where, with intensive ongoing
interventions, parasite prevalence in 2- to 5-year-olds fell from
42% to 18% between 2004 and 2008 [14]. Similarly, in the 1970s
Garki project in Nigeria, an area of moderate to high transmission
(annual EIRs in the range 20–130 ibppy), substantial declines in
prevalence were recorded but elimination was not achieved [7]. In
these settings, additional new tools are likely to be required if pre-
elimination targets are to be achieved.
Whilst a detailed comparison of the range of potential tools
under development is beyond the scope of this paper, there are
two broad areas of innovation that merit further consideration.
The first aims to target the mosquitoes that are not reached by
current interventions, particularly those on whom indoor-targeted
interventions are least successful. Notably, this includes major
species such as An. arabiensis, which preferentially rest outdoors
after feeding and may also obtain blood meals from non-human
animals. These mosquitoes could be targeted in a number of ways,
including additional interventions that are applied on non-human
hosts [72], killing adult females feeding or resting outdoors [73–
75], or at source in the larval habitat [76,77]. Secondly, our results
on the levels of human adherence required in high-transmission
settings suggest that interventions that do not strongly depend on
human participation are likely to be needed. The methods
outlined above are examples of such approaches.
Our results confirm findings by others that the bionomics of the
local vector species, including the degree of exophagy, exophily, and
zoophagy [35,36,78], can potentially be a strong determinant of
intervention success. Current tools, in particular LLINs and IRS, are
focused towards species with strong endophagic, endophilic, and
anthropophagic tendencies. Further data on the degree of endophilic
behaviour of the different Anopheles species, coupled with information
on how these parameters may change in response to interventions (we
assumed here that they remain fixed),are critically needed to
understand the longer-term impact of IRS and LLINs on
transmission. Historically, there is some evidence of species
replacement following the introduction of IRS in three different
geographical locations [79]. More recently, a shift in species relative
abundance (though not replacement or increased density) has been
observed in Western Kenya following high coverage of LLINs
[80,81]. In addition, mapping of vector species distribution and
proportional composition [17] is critical to the ability to predict
program success outside of the well-studied research areas.
Behavioural aspects of intervention programs are characterized
in multiple ways. For example, the WHO report bed-net coverage
as the number of nets distributed per person at risk [5], whilst
Malaria Indictor Surveys collect data on the proportion of
households owning a net or sleeping under a net [82]. Our results
demonstrate that patterns of coverage and effective coverage are
an important determinant of intervention success and may be one
reason why simple models of LLIN impact have tended to appear
highly optimistic [35–38]. Furthermore, it is unrealistic to assume
perfect and uniform adherence. Indeed, rates of sleeping under
LLINs tends to be highest in young children, but lower in school-
aged children [83], who are important contributors to the
infectious reservoir (Figure 1). Furthermore, whilst we did not
explicitly consider reduction in adherence or take-up of IRS, this is
likely to occur after repeated rounds as perceived risk declines, and
will reduce the impact of the intervention. Receipt of interventions
is also an important consideration in assessing impact, particularly
if coverage levels are low. It is well recognized that malaria
transmission is highly focal with some individuals at much higher
risk than others [42,43,64,84,85]. Our results confirm other
models’ findings [43,64] that, by targeting interventions at areas of
intense transmission, substantially greater reductions in transmis-
sion are possible than by distributing them randomly or by
focusing distribution towards younger children. However, little
attention has previously been paid to the heterogeneous
distribution of interventions within such target populations. In
general, the impact of an intervention will be lower if the same
individuals in the target population continually receive and adhere
to the intervention than if distribution fully covers the target
population. Thus data on repeat uptake of interventions would be
useful to determine true target population coverage levels.
Furthermore, health systems will need to be strengthened and
laboratory capacity put in place to allow rapid identification of
these foci. In addition, overall coverage levels can potentially be
enhanced through consideration of a wide range of different
delivery mechanisms appropriate to the local setting [86–88].
One aspect with the potential to hinder elimination campaigns
not considered here is the development of resistance—either to
drugs, to the insecticides used to treat nets or for indoor residual
spraying, or to vaccines—and the potential for alterations in the
behaviour of the vector in response to the interventions. Resistance
to DDT was a particular problem during the GMEP and is
credited with being a major reason for the abandonment of the
program. DDT resistance at varying levels has now been reported
in over 50 anopheline species [89]; thus, to reduce the further
emergence of resistance, elimination campaigns should aim to
reduce transmission as rapidly as possible. The recent emergence
of partial drug resistance to artemisinin in Cambodia [90] has
further highlighted the need to guard against and reduce the
emergence and spread of resistance, particularly as access to
treatment is scaled up.
Our model is necessarily a simplification of the more complex
dynamics underlying malaria transmission and control, so
numerical results should be interpreted more as providing intuitive
insight into potential scenarios than as firm predictions of what
might happen in a given setting. Furthermore, whilst we give an
indication of impact over a 25-year time horizon (including graphs
that track expected trends over this period), given the uncertainty
in some of the key parameters, it is not possible to give short-term
indications of impact or timelines. Precise, accurate prediction
remains challenging for a number of reasons. First, the mean
duration of asymptomatic infection, and the dynamics of
acquisition and loss of immunity, are key parameters determining
the speed of decline in parasite prevalence once transmission is
reduced [47]. These are both poorly understood in semi-immune
populations. These parameters also determine the time scale for
which interventions would need to remain in place to ensure that a
rebound in infection and disease does not occur. Current best
estimates of model parameters suggest that this is likely to be
decades rather than months or years, but further data are needed
to refine these estimates.
Second, there are multiple model structures that can reproduce
important characteristics of malaria epidemiology such as the age
patterns of infection prevalence across different transmission
settings. Whilst we have invested substantial effort in developing
a modern statistical framework to better choose between model
structures and to estimate associated model parameters, there are
limited data to distinguish some aspects of the model. In the
current exercise, we have focused on fitting the human model
cycle to a wide range of datasets. This will be extended in future
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applications to fit the full cycle using explicitly seasonal models to
more detailed data from specific research sites. In addition, the
individual intervention models have not to date been validated by
fitting to specific trial data. This process is underway. Such fitting
will enable the addition of uncertainty bounds to model output
through sampling of parameter posterior densities [91]. If feasible,
this could be extended to incorporate model uncertainty using a
Bayesian methodology [92].
Third, in our current model we use a relatively simple vector
cycle in which the vector population is driven by a constant birth
rate. This may underestimate the additional impact of interven-
tions that increase vector mortality and thus reduce population-
level fecundity. Vector models which incorporate capacity
constraints and behavioural change are a natural extension that
may better represent competition for larval habitats [93].
However, to date, such models have not been adequately
validated against weather measurements and entomological data
and thus further work is required to obtain a model that can
reproduce entomological patterns from multiple transmission
settings.
Last, our current model has been developed and parameterized
to be applied to single locations. It thus considers isolated areas
and does not address the focal and heterogeneous nature of
transmission on a wider spatial scale or the connectedness of local
populations. As such, the current model cannot be used to assess
the risk of reintroduction of the parasite from outside areas, which
has been shown to be a major challenge in ongoing control [94].
However, it is possible to extend this framework to a fully spatial
continental-scale simulator. The major challenge here is not in
developing the software tool but in parameterising the model
across settings. Basic requirements of such a model, e.g. human
population size in each area, are not well known across parts of
Africa, although synthetic data derived from satellite observations
can be used as a proxy [95,96]. In addition, such models require
local-level information on vector species, seasonality patterns,
intensity of transmission, and human movements to enable
assessment of the risks of transmission spatially.
Despite these limitations, mathematical models based on the
biology of the transmission cycle provide an appropriate tool for a
range of stakeholders to explore the potential impact of current
and future interventions on malaria transmission and disease
burden in a systematic manner. Further development of the
models and approaches outlined here can help to identify optimal
policies for the range of stages of malaria elimination programs
from the consolidation phase outlined here, through the pre-
elimination and elimination phases, to sustained elimination. By
considering current tools and exploring potential future interven-
tions, models can help us to understand the limits of current
strategies and evaluate the potential for future products to achieve
the ultimate goal of global eradication.
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Editors’ Summary
Background. Half the world’s population is at risk of
malaria, and every year nearly one million people—mainly
children living in sub-Saharan Africa—die from this
mosquito-borne parasitic disease. Most malarial deaths are
caused by Plasmodium falciparum, which is transmitted to
people by mainly night-biting Anopheles mosquitoes. When
infected mosquitoes feed on people, they inject sporozoites,
a parasitic form that replicates inside human liver cells. After
a few days, the liver cells release ‘‘merozoites,’’ which invade
red blood cells where they replicate rapidly before bursting
out and infecting more red blood cells. This increase in the
parasitic burden causes malaria’s characteristic fever.
Infected red blood cells also release ‘‘gametocytes,’’ which
infect mosquitoes when they take a blood meal. In the
mosquito, the gametocytes multiply and develop into
sporozoites, thus completing the parasite’s life cycle.
Malaria can be prevented by spraying the insides of
houses (where most Anopheles species feed and rest) with
insecticides (indoor residual spraying, IRS) and by sleeping
under bed nets that have been treated with long-lasting
insecticides (long-lasting insecticide nets, LLINs). Mass
screening and treatment (MSAT) with effective antimalarial
drugs can also reduce malaria transmission.
Why Was This Study Done? Early attempts to eradicate
malaria (reduce its global incidence to zero) in the 1950s
reduced the incidence of malaria to zero in some countries
(malaria elimination) and greatly reduced malarial illnesses and
deaths in others (malaria control). However, this eradication
program was aborted in the 1970s in part because of emerging
drug and insecticide resistance. Recently, the advent of
artemisinin-based combination therapies and new insecticides
and the prospect of a malaria vaccine have renewed interest in
controlling, eliminating, and ultimately eradicating malaria.
Consequently, in September 2008, the Roll Back Malaria
Partnership launched the Global Malaria Action Plan, which
aims to reduce malaria deaths to near zero by 2015. But are the
currently available tools for reducing malaria transmission
sufficient to control and eliminate malaria in Africa, the
continent where most malaria deaths occur? In this study, the
researchers use a new mathematical model of P. falciparum
transmission to investigate this question.
What Did the Researchers Do and Find? The
researchers’ P. falciparum transmission model consists of
‘‘compartments’’ through which individuals pass as they
become infected with parasites, develop immunity, become
infectious to mosquitoes, and so on. The researchers used
published data about parasite prevalence (the proportion of
the population infected with parasites) and about relevant
aspects of mosquito, parasite, and human biology, to
estimate the chances of an individual moving between
compartments. Finally, they used the model to explore the
impact over 25 years of increased coverage of LLINs, IRS, and
MSAT, and of a future vaccine on malaria transmission in six
representative African settings. In a low-transmission setting,
80% coverage with LLINs reduced the parasite prevalence to
below 1% in all age groups. In two moderate-transmission
settings, LLIN scale-up alone failed to reach this target but
the addition of IRS and MSAT drove the parasite prevalence
below 1%. However, this combination of interventions did
not control malaria in a moderate-transmission setting in
which a mosquito species that bites and rests outside houses
contributes to malaria transmission. Finally, in two high-
transmission settings, parasite prevalence could be driven
below 1% only by setting unrealistic coverage targets for
existing interventions.
What Do These Findings Mean? This new mathematical
model greatly simplifies the complex dynamics of malaria
transmission and includes several assumptions about which
there is considerable uncertainty. The findings of this study
are not, therefore, firm predictions of the future of malaria
control in specific settings. Nevertheless, they suggest that it
should be possible to make large reductions in malaria
transmission and the associated disease burden in Africa
over the next 25 years using currently available tools.
Specifically, in regions where transmission is low or
moderate and mosquitoes mainly feed indoors, it should
be possible to reduce parasite prevalence to less than 1%
provided a sustained intervention program is achieved.
Importantly, however, these findings suggest that in regions
where malaria transmission is high or where mosquitoes rest
and bite outside houses, new approaches will be needed to
control and eliminate malaria.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000324.
N Information is available from the World Health Organiza-
tion on malaria (in several languages); the 2009 World
Malaria Report provides details of the current global
malaria situation
N The US Centers for Disease Control and Prevention provide
information on malaria (in English and Spanish)
N Information is available from the Roll Back Malaria
Partnership on its approach to the global control of
malaria, including the Global Malaria Action Plan and a fact
sheet on malaria in Africa
N MedlinePlus provides links to additional information on
malaria (in English and Spanish)
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